Covalent Vaccine Complex for Multi-Epitopic T Cell Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer vaccines have limited clinical efficacy due to their inability to stimulate multi-epitopic cytotoxic T cell-mediated immunity, induce Th cells, and promote immunological memory, which are essential for generating potent and long-lasting anti-tumor immunity.
Innovation Solution
A novel complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, and at least one TLR peptide agonist, covalently linked for use in colorectal cancer immunotherapy. This complex aims to simultaneously stimulate multi-epitopic cytotoxic T cell-mediated immunity, induce Th cells, and promote immunological memory.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer vaccines are used, then they can be administered to patients, but they fail to stimulate multi-epitopic cytotoxic T cell-mediated immunity and induce Th cells
Solution Approach 1:
The vaccine complex is segmented into distinct functional components: a cell penetrating peptide for cellular uptake, multiple epitope sequences for diverse T cell recognition, and TLR agonist sequences for immune activation. This segmentation allows each component to perform its specific function while working together to overcome the limitations of conventional vaccines.
Solution Approach 2:
The invention creates a composite vaccine structure by covalently linking the cell penetrating peptide, multiple epitope sequences, and TLR agonist sequences into a single integrated complex. This composite structure ensures coordinated delivery and activation of multiple immune responses simultaneously, addressing the inadequacy of conventional single-antigen vaccines.
2Duration of action of stationary object
If conventional vaccines are used, then they can be produced and administered, but they cannot promote immunological memory
Solution Approach 1:
The vaccine complex is designed to preliminarily activate the immune system through TLR agonist sequences before presenting epitopes to T cells. This preliminary activation creates a primed immune environment that enhances subsequent memory formation, ensuring long-lasting immunity rather than transient responses.
Solution Approach 2:
The vaccine complex performs multiple functions simultaneously: it acts as a delivery vehicle (cell penetrating peptide), presents multiple antigens (multiple epitopes), and provides adjuvant activity (TLR agonist). This multi-functionality in a single structure promotes comprehensive immune activation including memory formation without requiring multiple separate vaccine components.
3Reliability
If simple vaccine structures are used, then they are easy to manufacture, but they lack the complexity needed to induce potent anti-tumor immunity
Solution Approach 1:
The invention merges multiple functional elements (cell penetrating peptide, epitope sequences, TLR agonist sequences) into a single covalently-linked polypeptide chain. This merging approach consolidates what would otherwise require multiple separate components into one molecule that can be produced using standard recombinant protein expression techniques, maintaining ease of manufacture while achieving complex immunological effects.
Data Source
AI summary
The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.